DR. SHANG, CATHERINE,DR. OPPERMANN, UDO,DR. MARTINEZ ESTRADA, FERNANDO,DR. LANGER, GERNOT,DR. OBENDORF, MAIK,DR. SACHER, FRANK
申请号：
ARP180101292
公开号：
AR111801A1
申请日:
2018.05.16
申请国别(地区):
AR
年份:
2019
代理人:
摘要：
It refers to a gpr84 receptor antagonist or inhibitor for the treatment and / or prevention of endocrine patients who may develop this disease and / or be diagnosed as endocrine, and the method of selecting this antagonist. Inhibitors and diagnostic methods, pharmaceutical ingredients. Requirement 1: a g84 protein coupled (gpr84) receptor antagonist or inhibitor, characterized by its use in the treatment and / or prevention of endocrinopathy of the uterus and the possibility of development of the patient,And / or diagnosed as endometrium. Claim 2: the counter cube or inhibitor referred to in claim 1, which is characterized by antibodies, preferably monoclonal antibodies, specifically binding to gpr84, or antigen binding or derivatives. Claim 9: the opposite cube or suppressor referred to in any one of the above requirements is characterized by limiting the activation of gpr84 induced by embelline with a value of ic832583205mm or less, preferably 10 mm or less, preferably 9.4 nm or less,The activation of gpr84 was initiated by Y / or 2-OH decanoic acid and ic8325； the activation of gpr84 was initiated by 83205mm or lower, preferably 10 mm or lower, preferably 16 nm or lower； and / or the activation of gpr84 was induced by 6-n-octalaminocilo and ic832525； the activation of gpr84 was initiated by 83205mm or lower, preferably 10 mm or lower, preferably 20 mm； The minimum or lower limit determined by one release test of gpr84 camp. 11. Claim 10: any counter party or inhibiting party referred to in claims 1 and 7 to 9, which is characterized by being a member of a target group on the dihydropyridinediene dimethyl ether list；Two pyridine Claim 11: according to any of the above requirements, the opposite cube is a homologue characterized by medium chain free fatty acids,And / or the enrichment of acid CoA sulfur sterase (ACAT) and / or isomerized fatty acid (FASN) in the isomerized endocrine； and / or the increase of gpr84 expression in the rich group extracted from the end
